PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
-0.68
Both companies show negative D/E. Martin Whitman would investigate if industry distress creates special situation opportunities.
-0.11
Net cash position while AGEN shows net debt of 1.06. Joel Greenblatt would examine if this balance sheet advantage creates strategic opportunities.
-6.94
Negative coverage while AGEN shows 6.84. Joel Greenblatt would look for operating improvements and turnaround potential.
0.01
Current ratio below 50% of AGEN's 4.71. Jim Chanos would check for potential working capital crisis.
No Data
No Data available this quarter, please select a different quarter.